Relevant conflicts of interest/financial disclosures: Cristina Sampaio is the chairperson of the permanent Steering Committee on the clinical development of pardoprunox and does not have any relevant personal financial interest to disclose. The research department to which Cristina Sampaio is affiliated has received research grants or fees from Astellas, Brane, Eisai, Fujisawa, Grünenthal, Kyowa, Lundbeck, Neurobiotech, Newron, Novartis, Schering-Plough, Serono, Servier, Solvay, UCB, and Xytis. Juliana Bronzova, Serge V. van de Witte, and Ad Theeuwes are employees of Solvay Pharmaceuticals (Solvay is now Abbott). Robert A. Hauser has received honoraria or consulting fees from Bayer Schering Pharma AG, Bertek, Boehringer Ingelheim, Centopharm, Eisai Ltd., Genzyme, GlaxoSmithKline, Impax, Kyowa Pharmaceutical, Merck KgaA, Novartis, Ortho McNeil, Pfizer, Prestwick, Schwarz Pharma, Schering, Solvay (member of the pardoprunox Development Steering Committee), Teva Neuroscience, Valeant, and Vernalis. Anthony E. Lang has received honoraria or consulting fees from Boehringer Ingelheim, Ceregene, Eisai, GlaxoSmithKline, Medtronic, Novartis, Prestwick, Solvay (member of the pardoprunox Development Steering Committee), Teva, and Valeant. Olivier Rascol has received scientific grants or consulting fees from Boehringer Ingelheim, Eisai Ltd., GlaxoSmithKline, Lundbeck, Novartis, Schering-Plough, Solvay (member of the pardoprunox Development Steering Committee), Teva Neuroscience, and UCB. Full financial disclosures and author roles may be found in the online version of this article.
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials†
Article first published online: 3 MAY 2011
Copyright © 2010 Movement Disorder Society
Volume 26, Issue 8, pages 1464–1476, July 2011
How to Cite
Sampaio, C., Bronzova, J., Hauser, R. A., Lang, A. E., Rascol, O., van de Witte, S. V., Theeuwes, a. A. and for the Rembrandt/Vermeer Study Groups (2011), Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov. Disord., 26: 1464–1476. doi: 10.1002/mds.23590
- Issue published online: 21 JUL 2011
- Article first published online: 3 MAY 2011
- Manuscript Accepted: 22 NOV 2010
- Manuscript Revised: 25 OCT 2010
- Manuscript Received: 14 JUL 2010
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.